Answers are grounded in this paper and cite their sources.
In vitro evaluation demonstrates enhanced photoluminescence and biocompatibility of boron-doped graphene oxide in T24 cancer cells, highlighting potential as safe bioimaging probes.
Boron-doped graphene oxide (BG) nanoparticles were synthesized via nanosecond pulsed laser ablation of graphene flakes in ethanol, using boric acid as the boron source and a post-ablation strategy. Structural and elemental analyses (Raman, FT-IR, and XPS) confirmed graphene oxidation and successful boron incorporation. FESEM and HRTEM revealed spherical nanoparticles with an average size of 30–60 nm. Optical studies showed excitation-dependent bluish-green photoluminescence with enhanced intensity and a high quantum yield (5.30 %) due to boron doping, while time-resolved spectroscopy indicated an increased average lifetime (2.54 ns). Biocompatibility studies demonstrated low cytotoxicity toward T24 cancer cells, with boron-rich samples exhibiting particularly high photostability. Efficient cellular internalization and stable emission under biological conditions highlight the potential of BG nanoparticles as safe and effective bioimaging probes.
No takes yet. Share an insight, caveat, or question.
Puliyasseri et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: